Draft:Treatments & Vaccines for COVID-19

Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine

Retrieved on:

Monday, November 2, 2020

Medicine, Health sciences, Medical research, Medical specialties, Vaccines, COVID-19 vaccine, Vaccine, Coronavirus disease, Severe acute respiratory syndrome, Draft:Treatments & Vaccines for COVID-19, COVID-19 drug development

NEW YORK, Nov. 2, 2020 /PRNewswire/ --Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company ,today announced key upcoming milestones towards the commercial development of the novel COVID-19 products currently being developed.

Key Points:

NEW YORK, Nov. 2, 2020 /PRNewswire/ --Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company ,today announced key upcoming milestones towards the commercial development of the novel COVID-19 products currently being developed.
Hoth Therapeutics has cast a wide net to contribute to the fight against COVID-19 that includes: HT-002 peptide therapeutic targeted to treat symptoms associated with COVID-19, the On-the-Go SARS-CoV-2 Testing Device , and VaxCelerate SARS-CoV-2 vaccine.
Pending results of the study, Hoth Therapeutics intends to pursue formulation development, preclinical safety testing, and meetings with the US Food and Drug Administration ("FDA") in 2021 for HT-002.
The SARS-CoV-2 vaccine is being developed using VaxCelerate, a self-assembling vaccine platform licensed from the Vaccine and Immunotherapy Center at Massachusetts General Hospital by HaloVax, LLC.

PepTC Vaccines Publishes Positive Preclinical Results for COVID-19 Peptide Vaccine That Shows Broad T Cell Response

Retrieved on:

Monday, October 19, 2020

Medical specialties, Medicine, Vaccination, Vaccine, Virology, Health, Medical research, Vaccines, COVID-19 vaccine, Draft:Treatments & Vaccines for COVID-19

LONDON, Oct. 19, 2020 (GLOBE NEWSWIRE) -- PepTC Vaccines Limited, a subsidiary of Treos Bio Limited, today announced the publication of positive preclinical results of its investigational PolyPEPI-SCoV-2 peptide vaccine.

Key Points:

LONDON, Oct. 19, 2020 (GLOBE NEWSWIRE) -- PepTC Vaccines Limited, a subsidiary of Treos Bio Limited, today announced the publication of positive preclinical results of its investigational PolyPEPI-SCoV-2 peptide vaccine.
PepTC Vaccines scientists designed the vaccine using PepTCs parent Treos Bios T cell vaccine development platform.
PepTC Vaccines expects to advance to human clinical studies for its investigational PolyPEPI-SCoV-2 vaccine during the fourth quarter of 2020.
PepTC Vaccines, a subsidiary of Treos, is focused on developing a broad and long-lasting global vaccine for COVID-19 (SARS-CoV-2).

Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)

Retrieved on:

Tuesday, October 13, 2020

Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Companys vaccine candidate against COVID-19.

Key Points:

Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Companys vaccine candidate against COVID-19.
Health Canada will not make a decision to authorize any vaccine being considered under rolling review until it has received all necessary evidence to support its safety and efficacy.
Following the authorization of any vaccine submission, Health Canada will publish the evidence used in making its decision for transparency.
Moderna remains on track to be able to deliver up to 56 million doses of its COVID-19 vaccine to help protect Canadians beginning in 2021.

NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets

Retrieved on:

Wednesday, October 7, 2020

Medicine, Health, Medical specialties, Medical research, Sarbecovirus, COVID-19 pandemic in Russia, Vaccines, COVID-19 vaccine, Severe acute respiratory syndrome, Coronavir, Draft:Treatments & Vaccines for COVID-19, Coalition for Epidemic Preparedness Innovations

Under the terms of the Agreement, Bintai will have an exclusive license to distribute the Ii-Key-SARS-CoV-2 vaccine in Southeast Asia, including Malaysia (pop.

Key Points:

Under the terms of the Agreement, Bintai will have an exclusive license to distribute the Ii-Key-SARS-CoV-2 vaccine in Southeast Asia, including Malaysia (pop.
Additionally, Bintai has been given an option, with right of first refusal for distribution in Australia (pop.
Generex CEO, Joseph Moscato said, With the closing of this Licensing and Distribution Agreement, we have secured the funding to complete the clinical development and regulatory work we need for approval of the Ii-Key- SARS-CoV-2 vaccine.
The company has also turned its Ii-Key technology on infectious disease, responding to the coronavirus pandemic with a SARS-CoV-2 vaccine development program.

Johnson & Johnson's One Dose COVID-19 Vaccine Trial with 60,000 Volunteers in Final Testing Phase

Retrieved on:

Monday, September 28, 2020

Articles, Health, Medical research, Vaccines, COVID-19 vaccine, Moderna, Pfizer, AstraZeneca, BioNTech, Johnson & Johnson, Vaccine, Draft:Treatments & Vaccines for COVID-19

Johnson & Johnson has begun final stage testing of its COVID-19 vaccine candidate.

Key Points:

Johnson & Johnson has begun final stage testing of its COVID-19 vaccine candidate.
The company will trial the vaccine with 60,000 volunteers from around the world including participants from the US, South Africa, Brazil, Argentina, Columbia, and Chile.
Johnson & Johnson's vaccine joins candidates developed by Moderna, Pfizer and BioNTech, and AstraZeneca and the University of Oxford in beginning the final stage of development.
In contrast to other vaccine candidates that require at least two doses, J & J's candidate requires just one dose.

Canada Exercises Increased Option for 20 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

Retrieved on:

Tuesday, September 22, 2020

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Canadian Government has increased its confirmed order commitment to 20 million doses of Modernas vaccine candidate against COVID-19, mRNA-1273.

Key Points:

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Canadian Government has increased its confirmed order commitment to 20 million doses of Modernas vaccine candidate against COVID-19, mRNA-1273.
This support, along with that of our stakeholders, drives us forward as we scale-up our global manufacturing and distribution network.
Moderna remains on track to be able to deliver up to 56 million doses of its COVID-19 vaccine to help protect Canadians beginning in 2021.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19

Retrieved on:

Monday, August 10, 2020

Health, FDA, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Drugs, Organic compounds, Gilead Sciences, Life sciences, Specialty drugs, Antivirals, COVID-19, Nucleotides, Remdesivir, Gilead, Stat, Draft:Treatments & Vaccines for COVID-19

Veklury is currently available in the U.S. under an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19.

Key Points:

Veklury is currently available in the U.S. under an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19.
Across studies, Veklury was generally well-tolerated in both the 5-day and 10-day treatment groups, with no new safety signals identified.
Please see below for additional important warnings and information about the authorized use of Veklury in the United States.
Gilead, the Gilead logo and Veklury are trademarks of Gilead Sciences, Inc. or its related companies.

GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update

Retrieved on:

Monday, August 10, 2020

Health, Medicine, Articles, Vaccines, Medical research, COVID-19 vaccine, Vaccine, Coronavirus disease, Novavax, Draft:Treatments & Vaccines for COVID-19

Company Demonstrated Progress on COVID-19 Vaccine Development;

Key Points:

Company Demonstrated Progress on COVID-19 Vaccine Development;
ATLANTA, GA, Aug. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE GeoVax Labs, Inc. (OTC: GOVX), a biotechnology company developing human vaccines, today announced financial results for the quarter ended June 30, 2020 and provided an update on its corporate developments.
In January 2020, GeoVax announced initiation of efforts to develop a vaccine against novel coronavirus disease (COVID-19) caused by the SARS-CoV-2 coronavirus.
Malaria Vaccine (collaboration with Leidos, Inc.) In February 2020, GeoVax expanded its ongoing collaboration with Leidos, Inc. to develop malaria vaccine candidates.
GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so.

Pfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate

Retrieved on:

Wednesday, August 5, 2020

Health, Articles, Vaccines, Medicine, COVID-19 vaccine, Medical research, Pfizer, Vaccine, Draft:Treatments & Vaccines for COVID-19, Gavi

As requested by the Government of Canada, deliveries of the vaccine candidate are planned for over the course of 2021.

Key Points:

As requested by the Government of Canada, deliveries of the vaccine candidate are planned for over the course of 2021.
As the development of effective COVID-19 vaccines continues around the world, we commend the work of Pfizer and BioNTech, which will provide Canadians access to a vaccine candidate for the virus.
This agreement is part of our commitment to address the pandemic by supporting global supply of our vaccine candidate.
The BNT162 program is based on BioNTechs proprietary mRNA technology and supported by Pfizers global vaccine development and manufacturing capabilities.

Global Phase 2/3 Clinical Trial for COVID-19 Vaccine Starts at NYU Langone Health

Retrieved on:

Tuesday, July 28, 2020

Health, Articles, Medical specialties, Bat virome, Sarbecovirus, Severe acute respiratory syndrome, Coronavirus disease, Pandemic, Vaccine, Science diplomacy and pandemics, Draft:Treatments & Vaccines for COVID-19

It is designed to measure whether the vaccine candidate can protect against COVID-19 infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Key Points:

It is designed to measure whether the vaccine candidate can protect against COVID-19 infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
"It is tremendously encouraging to see the early phase of this trial succeed, and to have a lead candidate emerge for global testing," says Mark J. Mulligan, MD, director of the Division of Infectious Diseases and Immunology and the Vaccine Center at NYU Langone Health.
NYU Langone Health was chosen as a trial center in part because of Dr. Mulligan's expertise in infectious disease research programs that have over decades assessed investigational vaccines for HIV, Zika, Ebola, and pandemic influenza.
The current, ongoing clinical trial began with a phase 1/2A study on May 4, 2020.